Dr. Eric Masson is Senior Vice President, Early Clinical Development at Arvinas. Dr. Masson has over 24 years of experience in the biotechnology industry and joins Arvinas after serving as Vice President, Clinical Pharmacology and Pharmacometrics at Biogen where he was responsible for those disciplines spanning from Investigational New Drug (IND) through Phase IV.
Prior to Biogen, Dr. Masson’s held leadership roles of increasing responsibility at AstraZeneca, Bristol-Myers Squibb, Novartis and Anapharm, Inc. Dr. Masson also served as a faculty member at the Université Laval in Quebec, Canada. Over his career, he played a key role in successful filings and approvals of the following medicines: Ipilimumab (Yervoy®), Nivolumab (Opdivo®), Osimertinib (Tagrisso®), Acalabrutinib (Calquence®), Diroximel Fumarate (Vumerity®), and Aducanumab (Aduhelm®).
Dr. Masson received his B.Pharm from Université Laval, his PharmD from the State University of New York at Buffalo and completed his postdoctoral fellowship in clinical pharmacology at St. Jude’s Children’s Research Hospital.
You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.
